Ignyta’s STARTRK-2 trial of entrectinib is now recruiting patients with fusions of the ROS1, ALK, and NTRK genes. Your doctor can order a no-cost test to see if your cancer has these gene fusions, and if you are a candidate for the STARTRK-2 clinical trial. This test, in most cases, can be performed on a tumor sample that was previously obtained and stored, avoiding the need for a new biopsy.

Learn What to Expect Along the Way

Navigating life after a cancer diagnosis can be overwhelming and stressful. There are many unknown factors and many critical decisions, all demanding attention. We want you to make a confident decision about whether to consider enrollment in STARTRK-2.

Here are some points to consider:

This clinical trial will evaluate the potential response of tumors with specific gene fusions to an investigational drug called entrectinib.

Adults with various types of cancer are invited to check their eligibility with our no-cost diagnostic test. Learn more if your diagnosis may make you eligible to participate.